F11 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This Target Evaluation Report for F11 is generated from PatSnap Life Sciences MCP data workflows, combining Target & Disease MCP biology context with Clinical Trials MCP validation and competitive signals.
For AI teams building biomedical agents, PatSnap Life Sciences MCP Servers provide structured retrieval across target biology, disease context, clinical trials, drug evidence, IP intelligence, and other R&D intelligence sources.
25 Direct drug records from Target & Disease MCP | 18 Development records in target context | 28 Disease associations captured | 138 Clinical trial records from Clinical Trials MCP |
Explore PatSnap Life Sciences MCP Servers for AI agents
Executive View
Biology Signal
F11 encodes coagulation factor XI, a node in the intrinsic coagulation pathway that activates factor IX. Target & Disease MCP shows a more focused footprint than F10, but with growing development interest.
Validation Evidence
F11 is attractive because it may decouple thrombosis prevention from bleeding risk better than traditional anticoagulant targets. The clinical thesis is compelling, but proof must come from outcomes and bleeding comparisons.
Competition and IP Pressure
Clinical Trials MCP returns 138 trial records, including early PK/PD studies and Phase 3 atrial fibrillation prevention. This is a rising target with meaningful but not yet F10-level competition.
Clinical Validation and Competitive Landscape
Clinical Trials MCP returned 138 registered trial records connected to F11. The sample below is used as a directional competitive readout rather than a full regulatory review.
| Trial | Phase | Status |
|---|---|---|
| YKYY033 Injection Safety, Tolerability, PK and PD Study | Phase 1 | Not yet recruiting |
| SRSD107 Safety, Tolerability, PK and PD in Healthy Chinese Subjects | Phase 1 | Completed |
| ROXI-EVEREST Stroke and Systemic Embolism Prevention in Atrial Fibrillation | Phase 3 | Not yet recruiting |
R&D Strategy Recommendation
For F11, prioritize programs that can demonstrate a better safety window in high-risk anticoagulation settings. MCP workflows should monitor Phase 3 readouts and modality differences across antibodies, small molecules, and RNA approaches.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
